Frei U, Wilks M F, Boehmer S, Crisp-Lindgren N, Schwarzrock R, Stiekema J C, Koch K M
Division of Nephrology, Medical School Hannover, FRG.
Nephrol Dial Transplant. 1988;3(4):435-9. doi: 10.1093/oxfordjournals.ndt.a091694.
In a randomised cross-over study we assessed total blood loss in 14 dialysis patients using 59Fe as a marker for measurement in a whole-body counting system. In one period the patients received standard heparin, in the other ORG 10172, a new low-molecular-weight-heparinoid. Our results show no significant difference between the two study periods with regard to blood loss and dialyser blood retention. In some patients a delayed bleeding ('oozing') from the puncture site was noticed as a side-effect of treatment with the low-molecular-weight-heparinoid. We conclude that this heparinoid is effective as an anticoagulant in regular dialysis treatment, but it seems to have no advantage over standard heparinisation with regard to occult bleeding. This may be related to the prolonged plasma anti-Xa activity (30.8 h) of this compound compared to standard heparin in dialysis patients.
在一项随机交叉研究中，我们使用59铁作为标记物，通过全身计数系统评估了14名透析患者的总失血量。在一个阶段，患者接受标准肝素治疗；在另一个阶段，接受ORG 10172（一种新型低分子肝素类似物）治疗。我们的结果显示，在失血和透析器血液潴留方面，两个研究阶段之间没有显著差异。在一些患者中，发现作为低分子肝素类似物治疗副作用的穿刺部位延迟出血（“渗血”）。我们得出结论，这种肝素类似物在常规透析治疗中作为抗凝剂是有效的，但在隐匿性出血方面似乎并不比标准肝素化有优势。这可能与该化合物在透析患者中与标准肝素相比延长的血浆抗Xa活性（30.8小时）有关。
